文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
侵权投诉

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

LETTER

doi:10.1038/nature13968

RoleofTP53mutationsintheoriginandevolutionoftherapy-relatedacutemyeloidleukaemia

TerrenceN.Wong1*,GiridharanRamsingh2*,AndrewL.Young3*,ChristopherA.Miller4,WaseemTouma1,JohnS.Welch1,5,TamaraL.Lamprecht1,DongShen6,JasreetHundal4,RobertS.Fulton4,SharonHeath1,JackD.Baty7,JefferyM.Klco8,LiDing1,5,ElaineR.Mardis4,5,9,PeterWestervelt1,5,JohnF.DiPersio1,5,MatthewJ.Walter1,5,TimothyA.Graubert1,5,TimothyJ.Ley1,5,ToddE.Druley3,DanielC.Link1,5&RichardK.Wilson4,5,9

Therapy-relatedacutemyeloidleukaemia(t-AML)andtherapy-relatedmyelodysplasticsyndrome(t-MDS)arewell-recognizedcomplicationsofcytotoxicchemotherapyand/orradiotherapy1.Thereareseveralfeaturesthatdistinguisht-AMLfromdenovoAML,includingahigherincidenceofTP53mutations2,3,abnormalitiesofchromosomes5or7,complexcytogeneticsandareducedresponsetochemotherapy4.However,itisnotclearhowpriorexposuretocytotoxictherapyinflu-encesleukaemogenesis.Inparticular,themechanismbywhichTP53mutationsareselectivelyenrichedint-AML/t-MDSisunknown.Here,bysequencingthegenomesof22patientswitht-AML,weshowthatthetotalnumberofsomaticsingle-nucleotidevariantsandtheper-centageofchemotherapy-relatedtransversionsaresimilarint-AMLanddenovoAML,indicatingthatpreviouschemotherapydoesnotinducegenome-wideDNAdamage.Weidentifiedfourcasesoft-AML/t-MDSinwhichtheexactTP53mutationfoundatdiagnosiswasalsopresentatlowfrequencies(0.003–0.7%)inmobilizedbloodleuko-cytesorbonemarrow3–6yearsbeforethedevelopmentoft-AML/t-MDS,includingtwocasesinwhichtherelevantTP53mutationwasdetectedbeforeanychemotherapy.Moreover,functionalTP53muta-tionswereidentifiedinsmallpopulationsofperipheralbloodcellsofhealthychemotherapy-naiveelderlyindividuals.Finally,inmousebonemarrowchimaerascontainingbothwild-typeandTp531/2hae-matopoieticstem/progenitorcells(HSPCs),theTp531/2HSPCspre-ferentiallyexpandedafterexposuretochemotherapy.ThesedatasuggestthatcytotoxictherapydoesnotdirectlyinduceTP53muta-tions.Rather,theysupportamodelinwhichrareHSPCscarryingage-relatedTP53mutationsareresistanttochemotherapyandex-pandpreferentiallyaftertreatment.TheearlyacquisitionofTP53mutationsinthefoundingHSPCcloneprobablycontributestothefrequentcytogeneticabnormalitiesandpoorresponsestochemo-therapythataretypicalofpatientswitht-AML/t-MDS.

t-AMLandt-MDSareclonalhaematopoieticdisordersthattypicallydevelop1–5yearsafterexposuretochemotherapyorradiotherapy1.TounderstandbetterhowpriorcytotoxictherapycontributestothehighincidenceofTP53mutationsandkaryotypicabnormalitiesint-AML/t-MDS,wesequencedthegenomesof22casesoft-AML,includingonecasethathasbeenpreviouslyreported5.Thesedatawerecomparedtowhole-genomesequencedatapreviouslyreportedfordenovoAML6andsecondaryAML(s-AML)arisingfromMDSforwhichpatientsdidnotreceivechemotherapyexcepthydroxyurea7,8.Ofthesequencedt-AMLcases,23%hadrearrangementsofMLL(alsoknownasKMT2A),23%hadcomplexcytogenetics,and36%hadnormalcytogenetics(ExtendedDataTable1andSupplementaryTable1).

WepredictedthatDNAdamageinducedduringexposuretocyto-toxictherapywouldmanifestitselfint-AMLgenomeswithanincreased

1

mutationburden.However,thetotalnumberofvalidatedsomaticsingle-nucleotidevariants(SNVs)andgenic(tier1)somaticSNVsidentifiedwassimilartothatfordenovoAMLands-AML(Fig.1a,b).Likewise,thenumberofsmallinsertionsordeletions(indels)ingenicregionswassimilarint-AML,denovoAMLands-AML(Fig.1c).Apreviousstudy

a

Total somatic SNVs

b

Tier 1 SNVs

cTier 1 indelsd

Transversions (%)

AML

e

AML

f

AML

Mutation type (%)

Number of clones

AMLL

Ls-AM

Mt-A

vo

no

g

Percentage with mutationDe

C

to GA to TC to CA to GC to T

A to

A

h

Percentage with mutation

ABTP5C3ST FmAG2PTKIPNTPK1H1PKD1UDL22AFTE1T2IDRUH1NNRAIX1S/DHKR2AFSNLT3DNPMM1T3A

Figure1|Themutationalburdenint-AMLissimilartodenovoAML.a,Totalnumberofvalidatedtier1–3somaticSNVsint-AML(n522),denovoAML(n549)ands-AML(n58).Themeanagesofthet-AML,denovoAMLands-AMLcohortswere55.7,51and54.6years,respectively.b,Numberofvalidatedtier1somaticSNVs.c,Numberofvalidatedtier1smallindels.d,Percentageoftier1–3somaticSNVsthataretransversions.e,Mutationalspectrumforallvalidatedtier1–3somaticSNVs.f,Numberofdistinctclonespersampleinferredfromtheidentificationofdiscreteclustersofmutationswithdistinctvariantallelefrequencies.g,Percentageofcasesoft-AML(n552)ordenovoAML(n5199)harbouringnon-synonymousmutationsoftheindicatedgene.h,Percentageofcasesoft-MDS(n559)ordenovoMDS(n5150)harbouringnon-synonymousmutationsoftheindicatedgene.ABCFm,ABCfamilygenes;NA,notavailable.{P,0.05byone-wayanalysisofvariance(ANOVA).*P,0.05byFisher’sexacttest.Datarepresentthemean6standarddeviation(s.d.).

DepartmentofMedicine,DivisionofOncology,WashingtonUniversity,StLouis,Missouri63110,USA.2DepartmentofMedicine,JaneAnneNohlDivisionofHematology,UniversityofSouthernCalifornia,LosAngeles,California90089,USA.3DepartmentofPediatrics,DivisionofHematology/Oncology,WashingtonUniversity,StLouis,Missouri63110,USA.4TheGenomeInstitute,WashingtonUniversity,StLouis,Missouri63110,USA.5SitemanCancerCenter,WashingtonUniversity,StLouis,Missouri63110,USA.6AstraZeneca,Gaithersburg,Maryland20878,USA.7DivisionofBiostatistics,WashingtonUniversity,StLouis,Missouri63110,USA.8DepartmentofPathologyandImmunology,WashingtonUniversity,StLouis,Missouri63110,USA.9DepartmentofGenetics,WashingtonUniversity,StLouis,Missouri63110,

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

USA.

*Theseauthorscontributedequallytothiswork.

00MONTH2014|VOL000|NATURE|1

TRUP53ABNXC1U Fm2AASF1OXLBS1EZCNNRAEH2S/TVKR6BCASSTORAGDNN2MF1T3TEAT2

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email